In summary, cytokine-armed DCPs improve tumor response to cisplatin and anti-PD-1 by eliciting IFNγ-producing T cells, decreasing tumor multiplicity and extending survival in two aggressive liver cancer models. This evidence concerns the gene IFNG and liver cancer.